Showing 8241-8250 of 9548 results for "".
- Modernizing Medicine Reveals Telemedicine Component for its EMRhttps://practicaldermatology.com/news/modernizing-medicine-reveals-telemedicine-component-for-its-emr/2458890/Modernizing Medicine, Inc. revealed a new t
- Provectus Receives Patent for Investigational Melanoma Agent PV-10https://practicaldermatology.com/news/provectus-receives-patient-for-investigational-melanoma-agent-pv-10/2458891/Provectus Biopharmaceuticals, Inc. has received a patent from the US Patent and Trademark Office, protecting the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver. Specifically, the patent covers the use of PV-10 in combination wit
- DermTube Kicks Off Video Coverage of SAAD in New Yorkhttps://practicaldermatology.com/news/dermtube-kicks-off-video-coverage-of-saad-in-new-york/2458889/With the American Academy of Dermatology meeting currently underway in New York, Practical Dermatology® magazine and DermTube have begun their joint video coverage of the event, with video interview with key opinion leaders. Su
- Nuvo Research Granted US Patent for Topical Onychomycosis Formulationhttps://practicaldermatology.com/news/nuvo-research-granted-us-patent-for-topical-onychomycosis-formulation/2458896/The United States Patent and Trademark Office granted a new U.S. patent number 9,084,754 ('754 Patent) to Nuvo Research Inc. for its highly permeating topical formulations of terbinafine, an antifungal drug, and methods for treating onychomycosis. The '754 Patent will expire on March 8, 2
- Miramar Labs to Launch miraSmooth Treatment with FDA Clearance of miraDry For Permanent Reduction of Underarm Hairhttps://practicaldermatology.com/news/miramar-labs-to-launch-mirasmooth-treatment-with-fda-clearance-of-miradry-for-permanent-reduction-of-underarm-hair/2458906/Miramar Labs’ miraDry® System received FDA clearance for the treatment of unwanted underarm hair, and permanent reduction of underarm hair of all colors. Miramar Lab's proprietary miraWave® technology—use of precisely controlled microwave energy—is the founda
- Lumenis to be Acquired by XIOhttps://practicaldermatology.com/news/lumenis-to-be-acquired-by-xio/2458924/
- Research Identifies Gene Linked to Melanoma Growth, Worse Outcomeshttps://practicaldermatology.com/news/research-identify-gene-linked-to-melanoma-growth-worse-outcomes/2458925/High levels of a specific protein linked to gene expression are associated with worse outcomes in melanoma, according to a study led by researchers at Icahn School of Medicine at Mount Sinai and published online in the journal Molecular Cell. Research shows that the protein, called H2A.Z.
- NIH Funding Often Does Not Match Disease Burden for Dermatologic Conditionshttps://practicaldermatology.com/news/nih-funding-often-does-not-match-disease-burden-for-dermatologic-conditions/2458930/A new analysis of funding prioritization by the National Institutes of Health for skin disease offers a glimpse of cutaneous skin disease on a national level, with some disease states being possibly underfunded. Examining the relationship between dermatologic research funding and skin disease bur
- TV Star, Mother of Four Larsa Pippen Shares Her UltraShape Storyhttps://practicaldermatology.com/news/ultrashape/2458944/UltraShape’s newest devotee, Larsa Pippen, Real Housewives of Miami Alumni, wife of six-time world champion NBA star Scottie Pippen, and fitness enthusiast, recently talked about her UltraShape experience, saying “UltraShape gives me more confidence. I eat well and exercise regularly,
- New Research Finds TriCalm Hydrogel's Itch Relief Superior to Leading OTC Treatmentshttps://practicaldermatology.com/news/new-research-finds-tricalm-hydrogels-itch-relief-superior-to-leading-otc-treatments/2458949/A study conducted to assess the antipruritic effect of over-the-counter (OTC) steroid-free topical hydrogel formulation TriCalm® in reducing itch intensity and duration, has been published in Clinical, Cosmetic, and Investigational Dermatology. The study, which utilized a co